Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

eUpdate – Nasopharyngeal Carcinoma Treatment Recommendations

ESMO–EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment for recurrent/metastatic disease

Ann Oncol. 2023;34(3):247-250.
P. Bossi, A. T. Chan , C. Even & J.-P. Machiels, on behalf of the ESMO Guidelines Committee

This update refers to Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. P. Bossi, A.T. Chan, L. Licitra et al. Ann Oncol 2021; 32(4): 452-465.

  • This special article provides updated treatment recommendations for nasopharyngeal carcinoma.
  • In high-risk locoregionally advanced NPC, the addition of metronomic or standard dose adjuvant capecitabine to CRT improves PFS.
  • Camrelizumab or toripalimab added to platinum and gemcitabine improves PFS as first-line metastatic treatment in endemic NPC areas.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.